Innoviva is part of the biotechnology industry and is in the healthcare sector. The company CEO is Eric d’Esparbes. Innoviva Inc is a biopharmaceutical company that is engaged in the discovery, development and commercialization of small molecule medicines. The firm collaborates with and receives funding from GlaxoSmithKline.
Previous Intraday Performance:
The INVA shares had a previous change of 2.96% which opened at 14.29 and closed at 14.60. It moved to an intraday high of 14.63 and a low of 14.25.
Over the last five trading days, INVA shares returned -0.41% and in the past 30 trading days it returned 5.64%. Over three months, it changed 2.38%. In one year it has changed -0.75% and within that year its 52-week high was 20.54 and its 52-week low was 13.07. INVA stock is 11.71% above its 52 Week Low.
Our calculations result in a 200 day moving average of 15.45 and a 50 day moving average of 14.10. Right now, INVA stock is trading -5.53% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
The company has a market cap of $1.5b with 101.3m shares outstanding and a float of 94.3m shares. Trading volume was 862,084 shares and has experienced an average volume of 885,309 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Innoviva was 3.53 which ended on 31st of December 2018, which according to the previous close, that is a PE of 4.14. The trailing twelve month EPS is 3.59, which comes to a trailing twelve month PE of 4.07.
Base on our calculations, the intrinsic value per share is 48.11, which means it might be undervalued and has a margin of safety of 69.65%
The next earnings report will be: 05-28-2019
The long-term trend of the EPS is an important number as it indicates the present value of Innoviva; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been 20.20% over the last twelve months.
Indicators Also to Watch:
I calculated the beta to be 1.73
Based on last reported financials, the company’s return on equity is -12,714.98%, return on assets is 94.82%, price-to-sales is 5.44 and price-to-book is 7.63.
Company Score Card:
Results are out of six:
1 : Growth Expectations Result
3 : Financial Safety Result
5 : Past Performance Result
4 : Valuation Result
0 : Dividend Safety Result
3 : Overall Result